BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36032073)

  • 1. Aging-based molecular classification and score system in ccRCC uncovers distinct prognosis, tumor immunogenicity, and treatment sensitivity.
    Zhu M; Huang C; Wu X; Gu Y; Hu X; Ma D; Zhong W
    Front Immunol; 2022; 13():877076. PubMed ID: 36032073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
    Pan H; Lu W; Zhang M; Liu C
    Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma.
    Gong Z; Xie J; Chen L; Tang Q; Hu Y; Xu A; Wang Z
    Channels (Austin); 2022 Dec; 16(1):84-96. PubMed ID: 35389815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of an immune prognostic classifier for clear cell renal cell carcinoma.
    Gu YY; Chen G; Lin P; Cheng JW; Huang ZG; Luo J; Zhai GQ; Wang YL; Yan HB; Li SH
    Cancer Biomark; 2020; 27(2):265-275. PubMed ID: 31929144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Methylation Modification Patterns Identify Distinct Prognosis and Responses to Immunotherapy and Targeted Therapy in Renal Cell Carcinoma.
    Bai D; Cheng Y; Lu X; Namasivayam GP; Sugiyama H
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):224. PubMed ID: 37796712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
    Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
    BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Evaluation of the m
    Yu M; Liu X; Xu H; Shen S; Wang F; Chen D; Li G; Wang Z; Zuo Z; Zhao A
    Front Immunol; 2022; 13():818120. PubMed ID: 35784363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis.
    Wang S; Wei X; Ji C; Wang Y; Zhang X; Cong R; Song N
    Front Oncol; 2022; 12():781932. PubMed ID: 35356208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
    Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
    J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.
    Zhang H; Liu Y; Wang B; Wang C
    BMC Genom Data; 2022 Jul; 23(1):58. PubMed ID: 35883015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
    Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
    Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients.
    Wang C; Hong T; Wang Y; Gan S; Wang Q; Li J; Zuo L; Cui X
    Oncoimmunology; 2020; 9(1):1736793. PubMed ID: 32313718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.